Ocugen Inc. closed 61.56% below its 52-week high of $2.08, which the company reached on April 8th.

Analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Ocugen in a research note issued ...

US-based biotechnology company Ocugen has received approval from the Data and Safety Monitoring Board (DSMB) to begin dosing ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

March 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported fourth quarter ...

Ocugen reported clinical trial progress and financial results, highlighting advancements in gene therapies for retinal diseases and recent FDA alignments. OCU410ST is a therapy for Stargardt ...

Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of dosing in the second cohort of the Phase 1 clinical trial for OCU200, a novel fusion protein ...

Shares of Ocugen Inc. OCGN climbed 12.13% to $0.71 Tuesday, on what proved to be an all-around positive trading session for ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data ...

March 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Data ...